Literature DB >> 33663442

Clinical utility of procalcitonin in febrile infants younger than 3 months of age visiting a pediatric emergency room: a retrospective single-center study.

Jun-Sung Park1, Young-Hoon Byun1, Jeong-Yong Lee1, Jong Seung Lee2, Jeong-Min Ryu2, Seung Jun Choi3.   

Abstract

BACKGROUND: Fever in infants under 90 days of age is highly likely to be caused by a severe bacterial infection (SBI) and it accounts for a large number of patients visiting the pediatric emergency room. In order to predict the bacterial infection and reduce unnecessary treatment, the classic classification system is based on white blood cell (WBC) count, urinalysis, and x-ray, and it is modified and applied at each center by incorporating recently studied biomarkers such as c-reactive protein (CRP) or procalcitonin (PCT). This study analyzed the usefulness of PCT in predicting SBI when applied along with the existing classification system, including CRP, among infants less than 90 days old who visited with a fever at a single institution pediatric emergency center.
METHODS: We retrospectively reviewed the medical records of patients younger than 3 months of age who presented with fever at the Seoul Asan Medical Center pediatric emergency room between July 2017 and October 2018.
RESULTS: A total of 317 patients were analyzed, and 61 were diagnosed with SBI, among which urinary tract infection (UTI) accounted for the largest proportion (55/61, 90.2%). There were differences in WBC, neutrophil proportion, CRP, and PCT between the SBI group and the non-SBI group, and the AUC values of WBC, CRP, and PCT were 0.651, 0.804, and 0.746, respectively. When using the cut-off values of CRP and PCTs as 2.0 mg/dL and 0.3 ng/mL, respectively, the sensitivity and specificity for SBI were 49.2/89.5, and 54.1/87.5, respectively. WBC, CRP, and PCT were statistically significant for predicting SBI in multivariate analysis (odds ratios 1.066, 1.377, and 1.291, respectively). When the subjects were classified using the existing classification criteria, WBC and CRP, the positive predictive value (PPV) and negative predictive value (NPV) were 29.3 and 88.7%, respectively, and when PCT was added, the PPV and NPV were 30.7 and 92%, respectively, both increased.
CONCLUSION: PCT is useful for predicting SBI in children aged 3 months or less who visit the emergency room with a fever. It is useful as a single biomarker, and when used in conjunction with classic biomarkers, its diagnostic accuracy is further increased.

Entities:  

Keywords:  Febrile infant; Neonate; Procalcitonin; Severe bacterial infection

Mesh:

Substances:

Year:  2021        PMID: 33663442      PMCID: PMC7931518          DOI: 10.1186/s12887-021-02568-5

Source DB:  PubMed          Journal:  BMC Pediatr        ISSN: 1471-2431            Impact factor:   2.125


  32 in total

1.  Low prevalence of invasive bacterial infection in febrile infants under 3 months of age with enterovirus infection.

Authors:  A Martínez Planas; C Muñoz Almagro; C Luaces Cubells; A Noguera Julián; L Selva; J Pou Fernández; J J García García
Journal:  Clin Microbiol Infect       Date:  2011-10-10       Impact factor: 8.067

2.  Procalcitonin as a marker of serious bacterial infections in febrile children younger than 3 years old.

Authors:  Prashant Mahajan; Mary Grzybowski; Xinguang Chen; Nirupama Kannikeswaran; Rachel Stanley; Bonita Singal; John Hoyle; Dominic Borgialli; Elizabeth Duffy; Nathan Kuppermann
Journal:  Acad Emerg Med       Date:  2014-02       Impact factor: 3.451

3.  Changing epidemiology of serious bacterial infections in febrile infants without localizing signs.

Authors:  Kevin Watt; Erica Waddle; Ravi Jhaveri
Journal:  PLoS One       Date:  2010-08-27       Impact factor: 3.240

4.  Diagnostic value of procalcitonin in well-appearing young febrile infants.

Authors:  Borja Gomez; Silvia Bressan; Santiago Mintegi; Liviana Da Dalt; Daniel Blazquez; Izaskun Olaciregui; Mercedes de la Torre; Miriam Palacios; Paola Berlese; Aitor Ruano
Journal:  Pediatrics       Date:  2012-10-29       Impact factor: 7.124

5.  Outpatient management without antibiotics of fever in selected infants.

Authors:  M D Baker; L M Bell; J R Avner
Journal:  N Engl J Med       Date:  1993-11-11       Impact factor: 91.245

6.  Procalcitonin increase after endotoxin injection in normal subjects.

Authors:  P Dandona; D Nix; M F Wilson; A Aljada; J Love; M Assicot; C Bohuon
Journal:  J Clin Endocrinol Metab       Date:  1994-12       Impact factor: 5.958

7.  Risk of Serious Bacterial Infection in Infants Aged ≤60 Days Presenting to Emergency Departments with a History of Fever Only.

Authors:  Sriram Ramgopal; Stephen Janofsky; Noel S Zuckerbraun; Octavio Ramilo; Prashant Mahajan; Nathan Kuppermann; Melissa A Vitale
Journal:  J Pediatr       Date:  2018-10-02       Impact factor: 4.406

8.  Febrile infants at low risk for serious bacterial infection--an appraisal of the Rochester criteria and implications for management. Febrile Infant Collaborative Study Group.

Authors:  J A Jaskiewicz; C A McCarthy; A C Richardson; K C White; D J Fisher; R Dagan; K R Powell
Journal:  Pediatrics       Date:  1994-09       Impact factor: 7.124

9.  Use of time from fever onset improves the diagnostic accuracy of C-reactive protein in identifying bacterial infections.

Authors:  Idan Segal; Matityahu Ehrlichman; Joseph Urbach; Maskit Bar-Meir
Journal:  Arch Dis Child       Date:  2014-05-15       Impact factor: 3.791

10.  Validity of bag urine culture for predicting urinary tract infections in febrile infants: a paired comparison of urine collection methods.

Authors:  Geun-A Kim; Ja-Wook Koo
Journal:  Korean J Pediatr       Date:  2015-05-22
View more
  1 in total

1.  Systematic review and meta-analysis assessing the diagnostic test accuracy of procalcitonin in the diagnosis of invasive bacterial infections in febrile infants: a study protocol.

Authors:  Hannah Norman-Bruce; Etimbuk Umana; Clare Mills; Lisa McFetridge; Hannah Mitchell; Tom Waterfield
Journal:  BMJ Open       Date:  2022-08-25       Impact factor: 3.006

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.